. 2021 Apr 29;24:1012–1023. doi: 10.1016/j.omtn.2021.04.007

Table 2.

Relationship between relative expression of ILF3-AS1/EZH2 and clinicopathological features in patients with CRC

Clinicopathologic data	n (58)	Expression of ILF3-AS1		p	Expression of EZH2		p
Clinicopathologic data	n (58)	Low expression group (n = 29)	High expression group (n = 29)	p	Low expression group (n = 29)	High expression group (n = 29)	p
Age (year)

≤60	41	19	22	0.565	21	20	1.000
>60	17	10	7	0.565	8	9	1.000

Gender

Male	36	16	20	0.417	17	19	0.787
Female	22	13	9	0.417	12	10	0.787

Tumor diameter (cm)

≤5	26	16	10	0.186	15	11	0.429
>5	32	13	19	0.186	14	18	0.429

LNM

N₀	21	15	6	0.028	16	5	0.006
N₁−N₃	37	14	23	0.028	13	24	0.006

Distant metastasis

M₀	43	27	16	0.002	26	17	0.015
M₁	15	2	13	0.002	3	12	0.015

Vascular invasion

Negative	37	23	14	0.028	24	13	0.006
Positive	21	6	15	0.028	5	16	0.006

Dukes stage

A + B	28	19	9	0.017	21	7	< 0.001
C + D	30	10	20	0.017	8	22	< 0.001

Degree of differentiation

High	26	15	11	0.477	16	10	0.264
Median	21	10	11		8	13
Low	11	4	7		5	6

Dukes A stage refers to the disease having not broken through the serosal layer in the mucosa or submucosa and the base layer of the intestinal wall. Dukes B stage refers to the cancer having invaded the serous membrane or tissues and organs but not yet occurred with lymph node metastasis (LNM). Dukes C stage refers to the cancer having been accompanied by LNM. Dukes D stage refers to the cancer usually being accompanied by distant organ metastasis.